Key result
AV-W9 gene therapy cuts neointimal hyperplasia ~40% after balloon injury in porcine coronary arteries.
Why the study?
Inhibition of proliferative neointima formed by vascular smooth muscle cells is a potential target to prevent angioplasty-induced restenosis, but effective therapies are needed.
Does AV-W9 gene therapy reduce angioplasty-induced neointimal hyperplasia in balloon-injured arteries?
Population
Rabbit carotid arteries and porcine coronary arteries subjected to balloon injury
Comparison
AV-W9 gene therapy vs untreated or control null virus (AV-null)
Design
Preclinical study with intravascular delivery of replication-deficient adenoviral vector
Follow-up
Up to 28 days
Authors
Loading...
AV-W9 gene therapy attenuates neointimal hyperplasia in animal models; leaves open translation to human restenosis prevention.
Does AV-W9 gene therapy reduce angioplasty-induced neointimal hyperplasia in balloon-injured arteries?
Absolute Event Rate: 0.42% vs 0.7%
Delivery of a p27-p16 fusion gene via adenoviral vector significantly inhibits balloon injury-induced neointimal hyperplasia in preclinical models, suggesting potential for preventing restenosis.
Tsui et al. (2001) studied Angioplasty-induced neointimal hyperplasia. AV-W9 (p27-p16 fusion protein adenoviral vector) vs. Untreated or control null virus (AV-null) was evaluated on Intimal area at 10 days. Intravascular delivery of AV-W9 gene therapy significantly inhibited neointimal hyperplasia in balloon-injured porcine coronary arteries compared with control virus (intimal area 0.42 vs 0.70 mm2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: